Russell Investments Group Ltd. Sells 25,067 Shares of Keros Therapeutics, Inc. $KROS

Key Points

• Russell Investments Group Ltd. significantly reduced its stake in Keros Therapeutics by 75.2% during the first quarter, now holding only 8,254 shares valued at $84,000.
• Keros Therapeutics has received various price target cuts from analysts, with Scotiabank reducing theirs from $41.00 to $26.00 and Bank of America revising theirs from $32.00 to $18.00.
• The company's stock opened at $15.76 and has experienced substantial price fluctuations, with a 12-month low of $9.12 and a high of $72.37.

Russell Investments Group Ltd. lowered its stake in Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) by 75.2% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 8,254 shares of the company's stock after selling 25,067 shares during the period. Russell Investments Group Ltd.'s holdings in Keros Therapeutics were worth $84,000 at the end of the most recent quarter.

A number of other institutional investors also recently bought and sold shares of KROS. Two Sigma Investments LP boosted its stake in Keros Therapeutics by 226.1% during the 4th quarter. Two Sigma Investments LP now owns 33,664 shares of the company's stock worth $533,000 after purchasing an additional 23,342 shares during the period. BNP Paribas Financial Markets acquired a new position in shares of Keros Therapeutics during the fourth quarter valued at $730,000. TFG Asset Management GP Ltd acquired a new stake in Keros Therapeutics during the fourth quarter valued at approximately $1,630,000. Northern Trust Corp raised its holdings in shares of Keros Therapeutics by 11.3% during the fourth quarter. Northern Trust Corp now owns 296,467 shares of the company's stock valued at $4,693,000 after acquiring an additional 30,111 shares during the period. Finally, The Manufacturers Life Insurance Company increased its stake in shares of Keros Therapeutics by 140.1% during the 4th quarter. The Manufacturers Life Insurance Company now owns 40,356 shares of the company's stock worth $639,000 after purchasing an additional 23,550 shares during the last quarter. 71.56% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

KROS has been the subject of a number of research analyst reports. Bank of America downgraded shares of Keros Therapeutics from a "buy" rating to a "neutral" rating and dropped their target price for the stock from $32.00 to $18.00 in a research note on Tuesday, June 10th. Scotiabank reduced their target price on shares of Keros Therapeutics from $41.00 to $26.00 and set a "sector outperform" rating for the company in a research note on Monday, May 12th. HC Wainwright decreased their target price on shares of Keros Therapeutics from $25.00 to $20.00 and set a "buy" rating on the stock in a research report on Friday, August 8th. Finally, Wedbush restated a "neutral" rating and set a $15.00 target price on shares of Keros Therapeutics in a research note on Friday, May 30th. Seven investment analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the company's stock. Based on data from MarketBeat, Keros Therapeutics presently has a consensus rating of "Moderate Buy" and a consensus target price of $30.00.

Keros Therapeutics Stock Up 0.2%

Shares of NASDAQ KROS traded up $0.03 during midday trading on Monday, hitting $15.62. The stock had a trading volume of 142,722 shares, compared to its average volume of 944,833. The company has a fifty day moving average price of $14.39 and a 200 day moving average price of $13.35. The company has a market capitalization of $634.28 million, a price-to-earnings ratio of 50.41, a PEG ratio of 2.01 and a beta of 1.06. Keros Therapeutics, Inc. has a 1-year low of $9.12 and a 1-year high of $72.37.

Keros Therapeutics (NASDAQ:KROS - Get Free Report) last announced its quarterly earnings data on Wednesday, August 6th. The company reported ($0.76) earnings per share for the quarter, beating the consensus estimate of ($1.14) by $0.38. Keros Therapeutics had a return on equity of 2.96% and a net margin of 8.06%.The business had revenue of $0.02 million during the quarter, compared to analyst estimates of $3.83 million. During the same quarter in the prior year, the firm posted ($1.25) earnings per share. The company's revenue was up 49002.7% on a year-over-year basis. On average, research analysts forecast that Keros Therapeutics, Inc. will post -4.74 EPS for the current year.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.